Literature DB >> 21924651

Failure of antimicrobial therapy to accelerate spontaneous healing of subclinical pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi.

Monica Venner1, Anne Rödiger, Marc Laemmer, Steeve Giguère.   

Abstract

Mass antimicrobial treatment of foals with small ultrasonographic pulmonary lesions is common on farms with endemic disease caused by Rhodococcus equi. The objectives of this study were to compare the relative efficacy of three antimicrobial protocols for the treatment of pulmonary abscesses on a farm with endemic infections caused by R. equi and to determine the frequency of spontaneous resolution of subclinical pulmonary lesions. Foals with ultrasonographic evidence of pulmonary abscesses ≥ 1.0 cm in diameter (n=128) were randomly allocated to one of four equal treatment groups. Animals with respiratory distress or severe pulmonary lesions were excluded from the study. Treatment groups consisted of: (1) tulathromycin intramuscularly; (2) azithromycin monotherapy orally; (3) azithromycin in combination with rifampin orally; and (4) glucose orally as a placebo. Physical examination, thoracic ultrasonography and white blood cell (WBC) counts were performed weekly by individuals unaware of treatment group assignment. Foals that worsened were removed from the study and treated with azithromycin and rifampin. Overall, 14/32 (43.8%) foals in the placebo group recovered without the need for therapy. The proportion of foals that responded to the initial therapy, the duration of therapy, the kinetics of ultrasonographic lesion resolution, the proportion of foals that had to be removed from the study and the number of days to removal from the study did not differ significantly between treatment groups. The study showed that many foals with pulmonary abscesses recover without antimicrobial therapy. Moreover, treatment of sub-clinically affected foals with antimicrobial agents did not significantly hasten recovery.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924651     DOI: 10.1016/j.tvjl.2011.07.004

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  22 in total

1.  vanO, a new glycopeptide resistance operon in environmental Rhodococcus equi isolates.

Authors:  Dereje Dadi Gudeta; Arshnee Moodley; Valeria Bortolaia; Luca Guardabassi
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

2.  Effect of Macrolide and Rifampin Resistance on Fitness of Rhodococcus equi during Intramacrophage Replication and In Vivo.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

3.  Effect of Macrolide and Rifampin Resistance on the Fitness of Rhodococcus equi.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère
Journal:  Appl Environ Microbiol       Date:  2019-03-22       Impact factor: 4.792

4.  Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.

Authors:  Laura Huber; Steeve Giguère; Nathan M Slovis; Craig N Carter; Bonnie S Barr; Noah D Cohen; Justine Elam; Erdal Erol; Stephan J Locke; Erica D Phillips; Jacqueline L Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 5.  Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-14       Impact factor: 11.056

6.  Fecal concentration of Rhodococcus equi determined by quantitative polymerase chain reaction of rectal swab samples to differentiate foals with pneumonia from healthy foals.

Authors:  Noah D Cohen; Patricia Flores-Ahlschewde; Giana M Gonzales; Susanne K Kahn; Bibiana Petri da Silveira; Jocelyne M Bray; Emily E King; Caroline C Blair; Angela I Bordin
Journal:  J Vet Intern Med       Date:  2022-04-27       Impact factor: 3.175

7.  Macrolide- and rifampin-resistant Rhodococcus equi on a horse breeding farm, Kentucky, USA.

Authors:  Alexandra J Burton; Steeve Giguère; Tracy L Sturgill; Londa J Berghaus; Nathan M Slovis; Jeremy L Whitman; Court Levering; Kyle R Kuskie; Noah D Cohen
Journal:  Emerg Infect Dis       Date:  2013-02       Impact factor: 6.883

8.  Composition and Diversity of the Fecal Microbiome and Inferred Fecal Metagenome Does Not Predict Subsequent Pneumonia Caused by Rhodococcus equi in Foals.

Authors:  Canaan M Whitfield-Cargile; Noah D Cohen; Jan Suchodolski; M Keith Chaffin; Cole M McQueen; Carolyn E Arnold; Scot E Dowd; Glenn P Blodgett
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

9.  Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007-2014.

Authors:  Caitriona S Fenton; Thomas C Buckley
Journal:  Ir Vet J       Date:  2015-10-06       Impact factor: 2.146

10.  Genotypic and phenotypic detection of efflux pump in Rhodococcus equi.

Authors:  Letícia Trevisan Gressler; Agueda Castagna de Vargas; Mateus Matiuzzi da Costa; Luciana Pötter; Bibiana Petri da Silveira; Luis Antônio Sangioni; Sônia de Avila Botton
Journal:  Braz J Microbiol       Date:  2014-08-29       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.